David D. Muth has been appointed to the newly created position of executive vice president, corporate development at Catalyst Pharmaceutical Partners. Mr. Muth will be responsible for all corporate development activities and will work with the Catalyst team in preparing a commercialization strategy for Firdapse. He reports to Patrick McEnany, chairman, president and chief executive officer of Catalyst.
 
Mr. Muth has more than 35 years of business experience in the pharma and biopharma industries, most recently serving as president and chief executive officer of Croma Pharmaceuticals Inc., where he established North American operations, gained approval of and launched 10 Ocular Surgical products. Prior to Croma, he was the global head of business development for Bausch + Lomb’s
Pharmaceutical Group, where he negotiated numerous transactions including company/products acquisitions and in-licensed a portfolio of programs.
 
“David’s appointment marks an important step in the growth of our
Company,” said Mr. McEnany. “He brings to the Catalyst team a broad skill set encompassing general management, corporate/business development, product development and launch, and strategic planning, as well as an outstanding track record of delivering results. We are excited that David is joining the company and believe that he will be a valuable resource to our management team.”